IPO Aftermarket: Analysts remain hopeful Twilio debut sparks more tech IPOs

Aeglea BioTherapeutics remains the lowest performing VC-backed company to debut this year

25 July 2016•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.